The estimated Net Worth of Andrew Perry is at least $1.43 Milión dollars as of 5 July 2024. Mr Perry owns over 1,337 units of G1 Therapeutics Inc stock worth over $802,938 and over the last 3 years he sold GTHX stock worth over $55,373. In addition, he makes $568,603 as Chief Commercial Officer at G1 Therapeutics Inc.
Mr has made over 5 trades of the G1 Therapeutics Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently he sold 1,337 units of GTHX stock worth $3,356 on 5 July 2024.
The largest trade he's ever made was selling 8,151 units of G1 Therapeutics Inc stock on 13 May 2024 worth over $39,043. On average, Mr trades about 1,453 units every 61 days since 2021. As of 5 July 2024 he still owns at least 112,614 units of G1 Therapeutics Inc stock.
You can see the complete history of Mr Perry stock trades at the bottom of the page.
Andrew Perry is the Chief Commercial Officer at G1 Therapeutics Inc.
As the Chief Commercial Officer of G1 Therapeutics Inc, the total compensation of Mr Perry at G1 Therapeutics Inc is $568,603. There are 11 executives at G1 Therapeutics Inc getting paid more, with Mark Avagliano having the highest compensation of $5,478,390.
Mr Perry is 48, he's been the Chief Commercial Officer of G1 Therapeutics Inc since . There are 19 older and 6 younger executives at G1 Therapeutics Inc. The oldest executive at G1 Therapeutics Inc is Fredric Eshelman, 72, who is the Independent Director.
Andrew's mailing address filed with the SEC is 700 PARK OFFICES DRIVE, SUITE 200, , RESEARCH TRIANGLE PARK, NC, 27709.
Over the last 8 years, insiders at G1 Therapeutics Inc have traded over $53,962,020 worth of G1 Therapeutics Inc stock and bought 1,541,753 units worth $24,259,954 . The most active insiders traders include Capital Management, L.P.Ra ..., Fredric N Eshelman a Glenn P Muir. On average, G1 Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $198,620. The most recent stock trade was executed by Andrew Perry on 5 July 2024, trading 1,337 units of GTHX stock currently worth $3,356.
g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.
G1 Therapeutics Inc executives and other stock owners filed with the SEC include: